| 64.25 -4.45 (-6.48%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 83.39 | 1-year : | 92.85 |
| Resists | First : | 71.4 | Second : | 79.5 |
| Pivot price | 71.51 |
|||
| Supports | First : | 58.29 | Second : | 48.5 |
| MAs | MA(5) : | 68.62 |
MA(20) : | 69.01  |
| MA(100) : | 74.42 |
MA(250) : | 66.38 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.5 |
D(3) : | 45.5 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 97.97 | Low : | 28.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SLGL ] has closed below the lower bollinger band by 4.8%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 70.1 - 70.46 | 70.46 - 70.75 |
| Low: | 66.9 - 67.27 | 67.27 - 67.58 |
| Close: | 68.16 - 68.74 | 68.74 - 69.22 |
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Fri, 16 Oct 2026
New Strong Buy Stocks for October 16th - Yahoo! Finance Canada
Thu, 15 Oct 2026
Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day - Slideshow (NASDAQ:SLGL) 2026-10-15 - Seeking Alpha
Thu, 08 Oct 2026
SolGel Technologies (SLGL) Upgraded to Buy: Here's Why - Yahoo Finance
Fri, 02 Oct 2026
Sol-Gel (SLGL) Stock Analysis: -1.37% Loss — Key Levels 2026-10-02 - Bollinger Expansion - dars.gov.et
Wed, 30 Sep 2026
Experts will discuss a rare genetic disorder and the lack of effective therapies at Sol-Gel's Oct. 14 event. - Stock Titan
Mon, 28 Sep 2026
Sol-Gel Technologies Ltd (SLGL-Q) Stock Price and News - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 59.6 (%) |
| Held by Institutions | 43 (%) |
| Shares Short | 146 (K) |
| Shares Short P.Month | 74 (K) |
| EPS | -5.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.68 |
| Profit Margin | 0 % |
| Operating Margin | -704.3 % |
| Return on Assets (ttm) | -23.9 % |
| Return on Equity (ttm) | -40.9 % |
| Qtrly Rev. Growth | -96.6 % |
| Gross Profit (p.s.) | -4.3 |
| Sales Per Share | 0.54 |
| EBITDA (p.s.) | -5.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -11.46 |
| PEG Ratio | 0 |
| Price to Book value | 4.37 |
| Price to Sales | 117.37 |
| Price to Cash Flow | -24.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|